Navigation Links
Covance to Present at Lehman Brothers 11th Annual Global Healthcare Conference
Date:3/18/2008

PRINCETON, N.J., March 18 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced that it will present at the Lehman Brothers 11th Annual Global Healthcare Conference on Wednesday, March 19, 2008 at 2:00 pm ET. Investors may access a live webcast of the presentation at http://www.covance.com. In order to register and download any necessary software, please log on 10 minutes early.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,700 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.


'/>"/>
SOURCE Covance Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Covance to Present at Raymond James 29th Annual Institutional Investors Conference
2. Covance to Present at UBS Global Healthcare Services Conference
3. Covance to Present at 26th Annual JPMorgan Healthcare Conference
4. Wendel Barr Appointed Chief Operating Officer of Covance
5. Covance and Care Partner on Rwanda Early Childhood Development Initiative
6. eResearchTechnology, Inc. to Announce Agreement to Acquire the Centralized ECG Business of Covance
7. eResearchTechnology (eRT) Agrees to Acquire the Centralized ECG Business of Covance
8. Covance Agrees to Enter Strategic Relationship with eResearchTechnology to Offer its Clients eRTs Centralized Cardiac Safety Services
9. Covance Elects Dr. Gary E. Costley to Board of Directors
10. Covance to Present at the UBS Global Life Sciences Conference
11. Hologic to Present at Lehman Brothers Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... DC (PRWEB) , ... March 30, 2017 , ... ... and organizations submitted a letter to President Trump expressing their support for an ... medical doctors, two Ph.D. scientists and one medical journalist, will hold a press ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... 2017 , ... Grass pollen is the main cause of hay fever in the United States, ... grass pollen runs from May to July each year; with the worst time for sufferers ... allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Sublime ... the "Spice of Life" or "Wonder Spice", it has been used for thousands of ... in the East," says Heshelow, author of " Turmeric: How to Use it For ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs ... store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these ... Ingredients in HeartBoost, an over the counter heart healthy drink, can reduce Arterial ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- Wound care devices and products are used to ... industry mainly consists of establishments engaged in manufacturing wound ... caused by mechanical, chemical, thermal, and radiogenic trauma; and ... skin related diseases, immunological diseases, and other chronic diseases. ... largest region in the wound care devices market in ...
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... N.J. , March 29, 2017  Novartis ... Administration (FDA) has accepted the company,s Biologics License ... CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T ... pediatric and young adult patients with B-cell acute ... submission by Novartis for a CAR-T. The priority ...
Breaking Medicine Technology: